Merck/Pfizer's Latest SGLT-2 Data Support Attractive Ertugliflozin/Januvia Combo
Overall, data suggest a profile similar to J&J's market-leading Invokana, but analysts still see room for a new entrant to the anti-SGLT-2 class in type 2 diabetes.
Overall, data suggest a profile similar to J&J's market-leading Invokana, but analysts still see room for a new entrant to the anti-SGLT-2 class in type 2 diabetes.